

# The impact of SARS-CoV-2 vaccines on antibody responses in the general population in the United Kingdom: Supplementary material

## Supplementary tables

	No evidence of prior infection			Evidence of prior infection			p value
	One dose AZ (N=23368)	One dose Pf (N=14894)	Two doses Pf(N=1869)	One dose AZ (N=3767)	One dose Pf (N=2067)	Total (N=45965)	
<b>Duration between two doses [Median (IQR)]</b>	31 (21-47)						
<b>Age</b>							< 0.001
<b>Median</b>	63	66	70	61	62	64	
<b>IQR</b>	55, 70	54, 73	53, 80	52, 68	50, 70	54, 71	
<b>Sex</b>							< 0.001
<b>Female</b>	12510 (53.5%)	8497 (57.0%)	1153 (61.7%)	2034 (54.0%)	1136 (55.0%)	25330 (55.1%)	
<b>Male</b>	10858 (46.5%)	6397 (43.0%)	716 (38.3%)	1733 (46.0%)	931 (45.0%)	20635 (44.9%)	
<b>Ethnicity</b>							< 0.001
<b>Non-white</b>	1110 (4.8%)	817 (5.5%)	118 (6.3%)	241 (6.4%)	148 (7.2%)	2434 (5.3%)	
<b>White</b>	22258 (95.2%)	14077 (94.5%)	1751 (93.7%)	3526 (93.6%)	1919 (92.8%)	43531 (94.7%)	
<b>Household size</b>							< 0.001
<b>1</b>	5019 (21.5%)	3302 (22.2%)	501 (26.8%)	721 (19.1%)	395 (19.1%)	9938 (21.6%)	
<b>2</b>	12990 (55.6%)	8260 (55.5%)	985 (52.7%)	1916 (50.9%)	1072 (51.9%)	25223 (54.9%)	
<b>3</b>	2863 (12.3%)	1688 (11.3%)	168 (9.0%)	545 (14.5%)	312 (15.1%)	5576 (12.1%)	
<b>4</b>	1797 (7.7%)	1130 (7.6%)	145 (7.8%)	403 (10.7%)	202 (9.8%)	3677 (8.0%)	
<b>5+</b>	699 (3.0%)	514 (3.5%)	70 (3.7%)	182 (4.8%)	86 (4.2%)	1551 (3.4%)	
<b>Deprivation percentile</b>							< 0.001
<b>Median</b>	63	64	64	60	57	63	
<b>IQR</b>	40, 82	40, 83	38, 83	35, 81	32, 79	39, 82	
<b>Report working in patient facing healthcare</b>							< 0.001
<b>No</b>	22860 (97.8%)	13430 (90.2%)	1466 (78.4%)	3636 (96.5%)	1828 (88.4%)	43220 (94.0%)	
<b>Yes</b>	508 (2.2%)	1464 (9.8%)	403 (21.6%)	131 (3.5%)	239 (11.6%)	2745 (6.0%)	
<b>Report working in person facing social care</b>							< 0.001
<b>No</b>	23149 (99.1%)	14548 (97.7%)	1800 (96.3%)	3717 (98.7%)	2014 (97.4%)	45228 (98.4%)	
<b>Yes</b>	219 (0.9%)	346 (2.3%)	69 (3.7%)	50 (1.3%)	53 (2.6%)	737 (1.6%)	
<b>Report working in a care home (any role)</b>							< 0.001
<b>No</b>	23195 (99.3%)	14551 (97.7%)	1778 (95.1%)	3701 (98.2%)	2011 (97.3%)	45236 (98.4%)	
<b>Yes</b>	173 (0.7%)	343 (2.3%)	91 (4.9%)	66 (1.8%)	56 (2.7%)	729 (1.6%)	
<b>Report having long-term health condition</b>							< 0.001
<b>No</b>	15774 (67.5%)	9597 (64.4%)	1217 (65.1%)	2645 (70.2%)	1398 (67.6%)	30631 (66.6%)	
<b>Yes</b>	7594 (32.5%)	5297 (35.6%)	652 (34.9%)	1122 (29.8%)	669 (32.4%)	15334 (33.4%)	

**Table S1. Participants' characteristics by cohort.** AZ: Oxford-AstraZeneca vaccine. Pf: Pfizer-BioNTech vaccine. Note: higher deprivation percentile means living in a less deprived area.

Time (days)	Age	No prior infection			Prior infection	
		AZ one dose	Pfizer one dose	Pfizer two doses	AZ one dose	Pfizer one dose
<b>Logistic model</b>		Predicted probability of anti-spike IgG positivity (95%CI)				
<b>0</b>	20	1 (0-3)	0 (0-1)	5 (1-16)	90 (82-95)	94 (88-97)
<b>0</b>	40	1 (0-1)	0 (0-1)	2 (1-5)	85 (80-88)	89 (84-92)
<b>0</b>	60	0 (0-0)	0 (0-0)	1 (1-2)	78 (75-82)	81 (77-84)
<b>0</b>	80	0 (0-0)	0 (0-0)	0 (0-1)	70 (61-78)	69 (59-77)
<b>7</b>	20	9 (4-20)	29 (17-45)	60 (34-81)	91 (83-96)	97 (94-99)
<b>7</b>	40	6 (4-10)	13 (9-18)	36 (23-52)	88 (83-91)	94 (90-96)
<b>7</b>	60	5 (4-6)	6 (4-8)	18 (12-25)	82 (78-85)	87 (83-90)
<b>7</b>	80	2 (1-4)	3 (2-5)	8 (4-14)	74 (66-81)	73 (64-81)
<b>14</b>	20	79 (62-90)	97 (92-99)	95 (87-98)	93 (86-97)	99 (97-100)
<b>14</b>	40	63 (55-71)	95 (92-97)	89 (80-94)	92 (89-94)	97 (95-99)
<b>14</b>	60	49 (44-53)	89 (86-91)	78 (70-83)	89 (87-92)	95 (93-96)
<b>14</b>	80	20 (14-28)	66 (59-72)	60 (49-70)	83 (76-88)	90 (84-93)
<b>21</b>	20	90 (77-96)	98 (94-99)	98 (93-99)	96 (89-98)	99 (97-100)
<b>21</b>	40	85 (78-90)	96 (94-98)	96 (91-98)	95 (92-97)	99 (97-99)
<b>21</b>	60	81 (77-84)	93 (91-95)	91 (87-94)	95 (93-96)	98 (97-98)
<b>21</b>	80	60 (52-68)	81 (75-85)	84 (77-89)	90 (85-93)	96 (93-98)
<b>28</b>	20	90 (74-96)	97 (93-99)	97 (89-99)	97 (92-99)	99 (97-100)
<b>28</b>	40	84 (76-89)	95 (92-97)	95 (90-98)	97 (94-98)	99 (98-100)
<b>28</b>	60	79 (75-83)	91 (89-93)	93 (89-95)	96 (95-97)	98 (97-99)
<b>28</b>	80	74 (66-80)	85 (80-89)	89 (84-93)	94 (90-96)	98 (95-99)
<b>35</b>	20	94 (79-99)	98 (95-99)	93 (83-98)	99 (93-100)	99 (97-100)
<b>35</b>	40	86 (78-91)	96 (93-97)	94 (88-97)	98 (95-99)	99 (98-100)
<b>35</b>	60	80 (75-84)	91 (89-93)	94 (91-96)	97 (96-98)	98 (97-99)
<b>35</b>	80	74 (67-80)	81 (76-85)	94 (90-97)	95 (92-97)	97 (95-99)
<b>42</b>	20	92 (72-98)	98 (94-99)	95 (86-98)	99 (93-100)	100 (98-100)
<b>42</b>	40	84 (75-90)	96 (93-97)	94 (88-97)	99 (95-100)	99 (98-100)
<b>42</b>	60	79 (73-84)	91 (88-93)	93 (89-95)	97 (95-99)	98 (97-99)
<b>42</b>	80	75 (67-81)	82 (77-86)	91 (85-95)	96 (91-98)	96 (93-98)
<b>49</b>	20	80 (39-96)	98 (94-99)	95 (87-98)	-	100 (98-100)
<b>49</b>	40	84 (71-92)	95 (92-97)	94 (89-97)	-	100 (97-100)
<b>49</b>	60	78 (67-86)	89 (85-92)	93 (89-95)	-	98 (96-99)
<b>49</b>	80	78 (67-86)	79 (74-84)	91 (85-94)	-	92 (86-96)
<b>Linear model</b>		Predicted anti-spike IgG levels in mAb units (95%CI)				
<b>0</b>	20	7 (5-9)	4 (3-6)	5 (3-8)	123 (82-185)	139 (90-216)
<b>0</b>	40	6 (5-7)	5 (5-6)	5 (4-7)	96 (78-119)	126 (102-156)
<b>0</b>	60	5 (5-6)	5 (4-5)	6 (5-7)	94 (81-108)	98 (83-115)
<b>0</b>	80	4 (4-5)	5 (4-5)	5 (4-6)	69 (53-90)	71 (55-92)
<b>7</b>	20	9 (7-12)	14 (11-18)	30 (17-52)	167 (111-251)	220 (141-342)
<b>7</b>	40	7 (7-8)	10 (9-11)	17 (13-22)	169 (136-210)	202 (162-250)
<b>7</b>	60	6 (6-6)	7 (7-8)	10 (8-12)	152 (132-176)	138 (117-163)
<b>7</b>	80	5 (4-5)	5 (5-5)	6 (5-8)	88 (67-117)	85 (66-108)


<b>14</b>	20	90 (71-115)	293 (228-375)	182 (110-301)	242 (155-376)	307 (204-464)
<b>14</b>	40	50 (45-56)	201 (181-225)	151 (117-196)	306 (243-386)	301 (244-371)
<b>14</b>	60	38 (36-40)	127 (119-137)	105 (86-128)	248 (214-287)	254 (217-298)
<b>14</b>	80	16 (15-19)	61 (56-67)	48 (39-58)	126 (96-166)	143 (113-181)
<b>21</b>	20	197 (152-257)	325 (258-409)	287 (173-478)	318 (197-514)	363 (243-542)
<b>21</b>	40	113 (100-127)	250 (225-277)	219 (171-280)	381 (299-485)	398 (324-489)
<b>21</b>	60	91 (85-97)	173 (162-185)	166 (136-202)	312 (267-365)	361 (307-424)
<b>21</b>	80	52 (47-58)	101 (93-110)	123 (103-147)	182 (141-236)	223 (174-286)
<b>28</b>	20	127 (94-171)	334 (266-420)	259 (153-440)	389 (237-639)	380 (245-591)
<b>28</b>	40	113 (99-129)	236 (214-261)	232 (179-301)	369 (286-477)	402 (324-497)
<b>28</b>	60	94 (87-100)	163 (153-175)	192 (158-232)	347 (291-413)	385 (328-452)
<b>28</b>	80	73 (65-81)	113 (104-123)	163 (136-196)	224 (173-290)	281 (221-356)
<b>35</b>	20	192 (135-274)	359 (278-464)	250 (157-400)	485 (274-860)	401 (250-644)
<b>35</b>	40	125 (108-144)	216 (193-242)	196 (157-246)	356 (267-476)	404 (321-508)
<b>35</b>	60	92 (85-100)	159 (148-171)	160 (133-193)	345 (283-420)	361 (305-429)
<b>35</b>	80	71 (64-79)	108 (99-117)	212 (180-251)	218 (165-288)	295 (234-372)
<b>42</b>	20	188 (123-288)	287 (221-373)	344 (215-551)	622 (251-1542)	424 (262-685)
<b>42</b>	40	93 (80-109)	202 (178-229)	244 (192-310)	412 (273-621)	411 (320-527)
<b>42</b>	60	86 (78-95)	146 (134-159)	191 (159-229)	335 (259-433)	353 (292-426)
<b>42</b>	80	74 (66-83)	94 (86-104)	175 (145-211)	200 (146-275)	280 (222-353)
<b>49</b>	20	107 (59-196)	269 (206-351)	382 (241-608)	-	450 (260-777)
<b>49</b>	40	108 (85-139)	177 (155-202)	264 (210-332)	-	441 (336-579)
<b>49</b>	60	79 (66-94)	117 (106-129)	218 (181-263)	-	385 (312-475)
<b>49</b>	80	73 (62-87)	81 (74-89)	220 (184-262)	-	273 (212-351)

**Table S2. Predicted probability of anti-spike IgG seropositivity and anti-spike IgG levels (in mAb units) with 95% confidence interval (CI) according to age, vaccine type and dose, and prior infection status by weeks after vaccination. AZ: Oxford-AstraZeneca vaccine. Pf: Pfizer-BioNTech vaccine.**


	Oxford-AstraZeneca					Pfizer-BioNTech				
	Class 1 (N=867)	Class 2 (N=7097)	Class 3 (N=13163)	Class 4 (N=1297)	p value	Class 1 (N=547)	Class 2 (N=8951)	Class 3 (N=3876)	Class 4 (N=720)	p value
<b>Percentage</b>	3.9%	31.6%	58.7%	5.8%		3.9%	63.5%	27.5%	5.1%	
<b>Age</b>					< 0.001					< 0.001
<b>Median</b>	58	60	64	68		64	62	72	71	
<b>IQR</b>	50, 66	48, 68	57, 70	60, 73		50, 73	49, 70	66, 77	62, 78	
<b>Age group</b>					< 0.001					< 0.001
<b>16-34</b>	73 (8.4%)	709 (10.0%)	167 (1.3%)	22 (1.7%)		63 (11.5%)	760 (8.5%)	12 (0.3%)	26 (3.6%)	
<b>35-54</b>	274 (31.6%)	1863 (26.3%)	2412 (18.3%)	165 (12.7%)		119 (21.8%)	2240 (25.0%)	231 (6.0%)	76 (10.6%)	
<b>55-74</b>	461 (53.2%)	4119 (58.0%)	9185 (69.8%)	862 (66.5%)		250 (45.7%)	4863 (54.3%)	2209 (57.0%)	354 (49.2%)	
<b>&gt;75</b>	59 (6.8%)	406 (5.7%)	1399 (10.6%)	248 (19.1%)		115 (21.0%)	1088 (12.2%)	1424 (36.7%)	264 (36.7%)	
<b>Sex</b>					< 0.001					< 0.001
<b>Female</b>	453 (52.2%)	4467 (62.9%)	6505 (49.4%)	600 (46.3%)		305 (55.8%)	5577 (62.3%)	1721 (44.4%)	364 (50.6%)	
<b>Male</b>	414 (47.8%)	2630 (37.1%)	6658 (50.6%)	697 (53.7%)		242 (44.2%)	3374 (37.7%)	2155 (55.6%)	356 (49.4%)	
<b>Report working in patient facing healthcare</b>					< 0.001					< 0.001
<b>No</b>	834 (96.2%)	6902 (97.3%)	12966 (98.5%)	1276 (98.4%)		475 (86.8%)	7976 (89.1%)	3791 (97.8%)	692 (96.1%)	
<b>Yes</b>	33 (3.8%)	195 (2.7%)	197 (1.5%)	21 (1.6%)		72 (13.2%)	975 (10.9%)	85 (2.2%)	28 (3.9%)	
<b>Report having long-term health condition</b>					< 0.001					< 0.001
<b>No</b>	592 (68.3%)	5104 (71.9%)	8859 (67.3%)	636 (49.0%)		355 (64.9%)	6219 (69.5%)	2096 (54.1%)	344 (47.8%)	
<b>Yes</b>	275 (31.7%)	1993 (28.1%)	4304 (32.7%)	661 (51.0%)		192 (35.1%)	2732 (30.5%)	1780 (45.9%)	376 (52.2%)	
<b>Membership probability (%)</b>					< 0.001					< 0.001
<b>Median</b>	98	82	71	99		94	89	86	100	
<b>IQR</b>	78, 100	61, 97	54, 92	84, 100		75, 100	74, 98	64, 97	91, 100	

**Table S3. Characteristics of classes identified from latent class mixed models for single dose Oxford-AstraZeneca and Pfizer-BioNTech vaccines in those without evidence of prior infection. Class 1='plausibly previously infected' group, 2='high response' group, 3='medium response' group, 4='low response group'.**


Supplementary figures



**Figure S1. Predicted probability of anti-spike IgG positivity by time from first vaccination and age, according to vaccine type and prior infection status (full model).** Predictions shown for specific ages in **Figure 1**. Observed data in **Supplementary Figures S3-S7**.




**Figure S2. Predicted probability of anti-spike IgG positivity by time from first vaccination for ages 20, 40, 60, and 80 years** (full models shown in **Figure S1**, plotted by vaccine in **Figure 1**). Line colour indicates different vaccine type and prior infection status. Data identical to **Figure 1**, but Figure 1 panels represent age rather than vaccine type as here.




**Figure S3. Percentage (95% CI) anti-spike IgG positive by days after first vaccination in participants receiving a single dose of Oxford-AstraZeneca vaccine and without evidence of prior infection. Results were divided into four age groups: 16-34, 35-54, 55-74, and >75 years.**




**Figure S4. Percentage (95% CI) anti-spike IgG positives by days after first vaccination in participants receiving a single dose of Oxford-AstraZeneca vaccine and with evidence of prior infection. Results were divided into four age groups: 16-34, 35-54, 55-74, and >75 years.**




**Figure S5. Percentage (95% CI) anti-spike IgG positives by days after first vaccination in people receiving a single dose of Pfizer-BioNTech vaccine and without evidence of prior infection. Results were divided into four age groups: 16-34, 35-54, 55-74, and >75 years.**




**Figure S6. Percentage (95% CI) anti-spike IgG positives by days after first vaccination in people receiving a single dose of Pfizer-BioNTech vaccine and with evidence of prior infection. Results were divided into four age groups: 16-34, 35-54, 55-74, and >75 years.**



**Figure S7. Percentage (95% CI) anti-spike IgG positives by days after first vaccination in people receiving two doses of Pfizer-BioNTech vaccine and without evidence of prior infection. Results were divided into four age groups: 16-34, 35-54, 55-74, and >75 years.**



**Figure S8. Predicted anti-spike IgG levels (in mAb units) by time from first vaccination and age, according to vaccine type and prior infection status (full model).** Predictions shown for specific ages in **Figure 3**.



**Figure S9. Age distribution by classes identified from latent class mixed models for single dose Oxford-AstraZeneca and Pfizer-BioNTech vaccines.** 1='plausibly previously infected' group, 2='high response' group, 3='medium response' group, 4='low response group'. Same area for each violin, see Table S3 for numbers in each group.